TABLE OF CONTENTS
Volume 12, Issue 1 (October 2005)
Editorial
Editorial: De-risking novel therapeutic development – time to stop blaming the molecule?
Simon Shohet
J Commer Biotechnol 12: 5-7; doi:10.1057/palgrave.jcb.3040142
Opinion
The European biotech sector: Could it achieve more?
Sam Fazeli
J Commer Biotechnol 12: 10-19; doi:10.1057/palgrave.jcb.3040143
Papers
What to do when your technology is good but a licence is terminated
Manon Cox and Dan Adams
J Commer Biotechnol 12: 22-28; doi:10.1057/palgrave.jcb.3040144
Future employment in biotechnology in Germany
Klaus Menrad
J Commer Biotechnol 12: 29-39; doi:10.1057/palgrave.jcb.3040145
Human Tissue Act 2004: The age of consent arrives in the UK
Gillian Johnson and Alex Wilson
J Commer Biotechnol 12: 40-44; doi:10.1057/palgrave.jcb.3040146
Rethinking innovation in pharmaceutical R&D
Ann Baker and Jasween Gill
J Commer Biotechnol 12: 45-49; doi:10.1057/palgrave.jcb.3040147
Managing innovation in the pharmaceutical industry
Esther F Schmid and Dennis A Smith
J Commer Biotechnol 12: 50-57; doi:10.1057/palgrave.jcb.3040148
Taking stock in biotechnology futures
John L Jacobs
J Commer Biotechnol 12: 58-60; doi:10.1057/palgrave.jcb.3040149
Biotechnology in India: Emerging opportunities
Himanshu Parmar
J Commer Biotechnol 12: 61-66; doi:10.1057/palgrave.jcb.3040150
Marketspace: Leading therapeutic recombinant protein sales forecast and analysis to 2010
Mark J Belsey and Alex K Pavlou
J Commer Biotechnol 12: 69-73; doi:10.1057/palgrave.jcb.3040151
